Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress
Lyell Immunopharma announced it will present updated safety and translational data from its Phase 1/2 trial of rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, in relapsed or refractory large B-cell lymphoma at the European Hematology Association Congress 2026. The data highlight low-grade side effects and durab…